Sniper Balloon Occlusion Microcatheter. Credit: Business Wire.

The US Food and Drug Administration (FDA) has granted 510(k) clearance to medical device company Embolx’s pressure-directed arterial embolisation system under the new Sniper Balloon Occlusion Microcatheters range.

The next-generation Sniper devices are intended for enhanced access and to facilitate easy navigation through small complex vascular structures.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Available in 110cm, 130cm and 150cm length variants, the microcatheter can be used to access femoral or radial arterial sites.

“The embolisation therapy is said to facilitate the delivery of drugs and embolic agents to the targeted treatment areas and at the same time protects surrounding healthy tissues.”

The company also added certain advancements to the balloon and made the tip design atraumatic in order to allow occlusion in large vessels and improve the device’s tracking ability inside the vessels.

Embolx president and CEO Michael Allen said: “Our next generation devices incorporate experience from more than 1,000 Sniper balloon occlusion microcatheters used to date.

“Now, interventional radiologists can do everything they would do with standard microcatheters, but with the added benefits of balloon occlusion. This is a big step forward and provides physicians with the most advanced transarterial delivery system for tumour and prostate treatment.”

The Sniper microcatheter is designed to control pressure in order to change blood flow‐dynamics and increase the delivery of therapeutic agents into target areas.

Currently, the device is used to treat cancerous tumours in various organs, including the liver, enlarged prostate (benign prostatic hyperplasia) and uterine fibroids.

The embolisation therapy is said to facilitate the delivery of drugs and embolic agents to the targeted treatment areas and at the same time protects surrounding healthy tissues.